NEUROONE MEDICAL TECHNOLOGIES Corp
For the period ended Sep 30, 2024. Filed Dec 17, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 17, 2024
NMTC$0.89+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Changes in Stockholders’ Equity
| Common Stock · Additional Paid–In · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance at September 30, 2022 | 16,216,540 | $16,217 | $60,414,959 | $(50,826,812) | $9,604,364 |
| Issuance of common stock in connection with public offering | 6,037,500 | 6,038 | 6,031,462 | — | 6,037,500 |
| Issuance of common stock in connection with at-the-market offering program | 1,439,677 | 1,440 | 2,551,216 | — | 2,552,656 |
| Issuance costs in connection with common stock issuances | — | — | (1,071,663) | — | (1,071,663) |
| Stock-based compensation | — | — | 1,105,457 | — | 1,105,457 |
| Issuance of common stock upon vesting of restricted stock units | 314,485 | 313 | (313) | — | — |
| Share repurchases for the payment of employee taxes | (79,257) | (79) | (119,340) | — | (119,419) |
| Net loss | (11,859,491) | (11,859,491) | |||
| Balance at September 30, 2023 | 23,928,945 | 23,929 | 68,911,778 | (62,686,303) | 6,249,404 |
| Issuance of common stock in connection with 2024 Private Placement | 2,944,446 | 2,944 | 833,833 | — | 836,777 |
| Issuance of common stock in connection with at-the-market offering program | 3,748,913 | 3,749 | 5,030,157 | — | 5,033,906 |
| Issuance costs in connection with common stock issuances | — | — | (296,161) | — | (296,161) |
| Stock-based compensation | — | — | 1,344,476 | — | 1,344,476 |
| Issuance of common stock upon vesting of restricted stock units | 267,305 | 267 | (267) | — | — |
| Share repurchases for the payment of employee taxes | (73,110) | (73) | (81,330) | — | (81,403) |
| Issuance of warrants in connection with debt facility | — | — | 53,124 | — | 53,124 |
| Net loss | — | — | — | (12,318,110) | (12,318,110) |
| Balance at September 30, 2024 | 30,816,499 | $30,816 | $75,795,610 | $(75,004,413) | $822,013 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.